5
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Topical retapamulin in the management of infected traumatic skin lesions

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Retapamulin is a novel semisynthetic pleuromutilin antibiotic specifically designed for use as a topical agent. The unique mode of action by which retapamulin selectively inhibits bacterial protein synthesis differentiates it from other nonpleuromutilin antibacterial agents that target the ribosome or ribosomal factors, minimizing the potential for target-specific cross-resistance with other antibacterial classes in current use. In vitro studies show that retapamulin has high potency against the Gram-positive bacteria ( Staphylococcus aureus, Streptococcus pyogenes, and coagulase-negative staphylococci) commonly found in skin and skin-structure infections (SSSIs), including S. aureus strains with resistance to agents such as macrolides, fusidic acid, or mupirocin, and other less common organisms associated with SSSIs, anaerobes, and common respiratory tract pathogens. Clinical studies have shown that twice-daily topical retapamulin for 5 days is comparable to 10 days of oral cephalexin in the treatment of secondarily infected traumatic lesions. A 1% concentration of retapamulin ointment has been approved for clinical use as an easily applied treatment with a short, convenient dosing regimen for impetigo. Given the novel mode of action, low potential for cross-resistance with established antibacterial agents, and high in vitro potency against many bacterial pathogens commonly recovered from SSSIs, retapamulin is a valuable enhancement over existing therapeutic options.

          Author and article information

          Journal
          Ther Clin Risk Manag
          Therapeutics and Clinical Risk Management
          Therapeutics and Clinical Risk Management
          Dove Medical Press
          1176-6336
          1178-203X
          2009
          2009
          26 March 2009
          : 5
          : 41-49
          Affiliations
          [1 ]Infectious Disease Center for Excellence in Drug Discovery, GlaxoSmithKline, Collegeville, PA, USA;
          [2 ]Anti-infectives Medicine Development Center, GlaxoSmithKline, Collegeville, PA, USA;
          [3 ]Infectious Diseases Medicine Development Centre, Europe, GlaxoSmithKline, Greenford, Middlesex, UK;
          [4 ]MDC BDS – Infectious Disease, GlaxoSmithKline, Collegeville, PA, USA;
          [5 ]Anti-infectives Medicine Development Center, GlaxoSmithKline, Research Triangle Park, NC, USA
          Author notes
          Correspondence: Nicole Scangarella-Oman, Infectious Disease Center for Excellence in Drug Discovery, GlaxoSmithKline, 1250 South Collegeville Road, Mailcode, UP1345, Collegeville, PA 19426, USA, Tel +1 610 917 4023, Fax +1 610 917 7901, Email Nicole_E_Scangarella-Oman@ 123456gsk.com
          Article
          tcrm-5-0041
          2697516
          19436611
          3965e217-f8ef-486c-bdc5-1c62f77a582b
          © 2009 Shawar et al, publisher and licensee Dove Medical Press Ltd.

          This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited.

          History
          Categories
          Review

          Medicine
          traumatic skin lesions,staphylococcus aureus,retapamulin,topical antibiotic,skin infections

          Comments

          Comment on this article